A Phase 1 interventional study of ABBV-932 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of ABBV-932 on day 1.
Drug: ABBV-932
Oral Capsule
Maximum Plasma Concentration (Cmax) of ABBV-932
Cmax of ABBV-932
Time frame: Up to approximately 86 days
Time to Cmax (Tmax) of ABBV-932
Tmax of ABBV-932
Time frame: Up to approximately 86 days
Terminal phase elimination rate constant (λz) of ABBV-932
Terminal phase elimination rate constant (λz) of ABBV-932
Time frame: Up to approximately 86 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932
Terminal phase elimination half-life of ABBV-932
Time frame: Up to approximately 86 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932
AUCt of ABBV-932
Time frame: Up to approximately 86 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932
AUCinf of ABBV-932
Time frame: Up to approximately 86 days
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 103 days
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2026 to primary completion in Sep 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-932